Lakhani S, Selby P, Bliss J M, Perren T J, Gore M E, McElwain T J
Section of Medicine, Royal Marsden Hospital, Sutton, Surrey, UK.
Br J Cancer. 1990 Feb;61(2):330-4. doi: 10.1038/bjc.1990.65.
In a consecutive series of studies, 164 patients with symptomatic and/or visceral metastatic malignant melanoma were treated with single agent vindesine, high dose melphalan with autologous bone marrow transplantation (AMBT), high dose BCNU with ABMT or the BOLD (bleomycin, vincristine, CCNU and DTIC) combination. The high dose treatments and the combination chemotherapy resulted in significantly higher response rates but no prolongation of survival. Factors associated with longer survival included the absence of visceral metastases, the absence of bulky disease and good performance status. For all treatments, life table estimates of survival at 1 and 2 years were only 10% and 4% respectively.
在一系列连贯的研究中，164例有症状的和/或内脏转移的恶性黑色素瘤患者接受了单一药物长春地辛、高剂量美法仑联合自体骨髓移植（AMBT）、高剂量卡莫司汀联合ABMT或BOLD（博来霉素、长春新碱、洛莫司汀和达卡巴嗪）联合化疗。高剂量治疗和联合化疗导致显著更高的缓解率，但生存期并未延长。与较长生存期相关的因素包括无内脏转移、无大块病灶和良好的身体状况。对于所有治疗，1年和2年生存率的生命表估计分别仅为10%和4%。
